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Abstract In schizophrenia, treatments that improve out-
comes have not been reliably disseminated. A major barrier
to improving care has been a lack of routinely collected
outcomes data that identify patients who are failing to
improve or not receiving effective treatments. To support
high quality care, the VA Mental Health QUERI used liter-
ature review, expert interviews, and a national panel process
to increase consensus regarding outcomes monitoring
instrumentsandstrategiesthatsupportqualityimprovement.
There was very good consensus in the domains of psychotic
symptoms, side-effects, drugs and alcohol, depression,
caregivers, vocational functioning, and community tenure.
There are validated instruments and assessment strategies
that are feasible for quality improvement in routine practice.
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Introduction
Psychosocial and medication treatments have consistently
and repeatedly been found to improve outcomes in
schizophrenia (American Psychiatric Association 2004;
Kreyenbuhl et al. 2010). However, key evidence-based
treatments have not been widely disseminated (Institute of
Medicine 2006; Lehman 1999; President’s New Freedom
Commission on Mental Health 2003). Increasingly, policy
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improving the quality of care. One leading approach to
improving care starts by identifying patients who would
beneﬁt from a speciﬁc evidence-based treatment, and then
ensuring that they have access to that treatment (Ruben-
stein et al. 2000). While this approach has improved out-
comes in chronic disorders such as diabetes (Asch et al.
2004; Kupersmith et al. 2007), it has proven very difﬁcult
to implement in mental illness, and especially schizo-
phrenia (Young et al. 2004). A major challenge has been a
lack of valid, routinely collected outcomes data to identify
patients who are failing to improve clinically and func-
tionally, or who are not receiving appropriate care. In part,
the lack of such data reﬂects uncertainty regarding which
outcome domains to monitor and how to feasibly collect
routine outcomes data in large populations of patients.
Quality improvement efforts would beneﬁt from better
consensus regarding methods for routine monitoring of
outcomes of schizophrenia.
Most successful efforts to improve healthcare quality
have been conducted outside of mental health, and few
have occurred in schizophrenia. In diabetes, for example,
medical records and electronic data routinely include
information needed to evaluate and improve care. These
include data on demographics, hemoglobin A1c (HgA1c, a
measure of diabetes severity), prescriptions, and proce-
dures received. Since HgA1c and prescription data are
routinely collected and recorded electronically, policy
makers have been able to identify patients who have poorly
controlled diabetes and apply national quality improvement
efforts to improve diabetes care. In schizophrenia, there are
also measures of illness severity and need for treatment. At
present, however, these outcomes are not reliably docu-
mented in medical records (Young et al. 2004). As a result,
policy makers have had difﬁculty determining the extent to
which quality improvement and additional treatment
resources would have value in schizophrenia.
There are multiple barriers to gathering outcome data in
schizophrenia. Outcome assessment methods used in
researchprotocolshaveprovedtoocostlyandtime-intensive
to widely adopt in routine practice. Clinicians can be trained
to achieve high levels of reliability in standardized instru-
ments such as the Brief Psychiatric Rating Scale (Ventura
et al. 1993). However, substantial staff time is required for
administration and for training required to achieve and
maintain adequate reliability. Most provider organizations
cannot afford to dedicate staff to this assessment role or to
intensively train staff to reliably perform assessments.
There are alternative strategies for outcomes monitor-
ing. These include monitoring based on billing or admin-
istrative data, assessment by clinicians without intensive
training in standardized instruments, or patient self-
assessment. Administrative and billing data are relatively
easy to obtain for large patient populations, and can be
used to track basic demographics and sometimes medica-
tion prescriptions. However, these data can be inaccurate or
incomplete, and lack detailed clinical content. Alterna-
tively, it is possible to ask clinicians to routinely complete
rating instruments as part of treatment visits, without
intensive training and reliability checks. Some organiza-
tions have, for example, mandated regular assessments
using the Global Assessment of Functioning (GAF) Scale.
This has met with limited success. Reliability with
untrained raters is very poor (Niv et al. 2007b) and many
clinicians resist incorporating standardized rating and
documentation into routine practice. In contrast, monitor-
ing based on patient self-report and/or self-assessment is
relatively easy to implement in clinical settings (Brown
et al. 2005; Chinman et al. 2007). While validity varies, it
can be quite good with certain domains and instruments
(Eisen et al. 2004). In addition, there is inherent value in
patient-centered assessment (Niv et al. 2007a).
This manuscript describes a process within the U.S.
Department of Veterans Affairs (VA) to (1) identify out-
come indicators that can be used for routine monitoring in
support of projects to improve the quality of care for
schizophrenia, and (2) identify instruments and methods
for monitoring these outcome indicators. The VA provides
care for more than 100,000 people with schizophrenia and
is a national leader in healthcare quality and the use of
clinical information systems to improve care (Jha et al.
2003; Kupersmith et al. 2007). In 1998, the VA established
a national Quality Enhancement Research Initiative
(QUERI) to inform quality improvement and identify
effective strategies for implementing research evidence
into routine clinical practice across nine disorders (Francis
and Perlin 2006; McQueen et al. 2004). The Mental Health
QUERI focuses on improving care delivered to individuals
with depression and schizophrenia, and is a partnership
between leading national researchers, policy makers, and
treatment experts. Since prior efforts to develop outcome
measurement in schizophrenia (Cuffel et al. 1997; Veterans
Health Administration 2003) did not meet the QUERI’s
goals, a Schizophrenia Outcomes Workgroup was con-
vened in August 2004. This manuscript presents the
methods used and products developed by this Workgroup.
Methods
The ﬁrst task of the Workgroup was to identify outcome
domains that can support implementation of high-priority,
evidence-based treatments. Based on a review of national
treatment guidelines and the new emphasis on recovery, the
Workgroup chose to focus on the following outcomes:
psychotic symptoms, medication side-effects, drug and
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123alcohol use, depression, family and caregivers, vocational
functioning, community tenure and housing. The domains
of negative and cognitive symptoms were acknowledged to
also be important, but were not included because national
guidelines do not contain evidence-based practices to
improve these outcomes. Comorbid medical conditions
were also acknowledged as critically important, since
patients with schizophrenia are at high risk for a variety of
medical problems, including diabetes mellitus, cardiovas-
cular disease, hypertension, chronic obstructive pulmonary
disease, and infectious diseases (American Psychiatric
Association 2004). However, development of consensus in
this area would require review of a very large body of
guidelines from outside of specialty mental health, and was
beyond the scope of this Workgroup.
For each domain, the Workgroup sought to identify
indicators of: (a) need for treatment, and (b) change in
clinical status associated with treatment. Potential assess-
ment strategies, including patient self-assessment, rater or
clinician-based assessment, and use of administrative or
billing data, were reviewed. It was agreed that feasibility of
routine assessment and documentation was critical, and
therefore this manuscript focuses on self-report and
administrative data approaches. The Workgroup recog-
nized that to improve care, it is also necessary to know
whether patients who need treatment have received it. This
can be assessed using data on treatment utilization and
treatment ﬁdelity. While this data is quite important, dis-
cussion of alternatives for assessing treatment utilization
and ﬁdelity indicators was beyond the scope of this
Workgroup.
A modiﬁed Delphi process was used to increase con-
sensus regarding outcomes monitoring options (Fitch et al.
2001). This process included literature review, expert
interviews, and a national panel of experts and stakehold-
ers. The literature review covered published journal articles
and books, unpublished documents on treatment and out-
come assessment in schizophrenia, plus communication via
phone and email with key informants. These informants
included experts who had published on schizophrenia
outcome assessment, Workgroup members, and individuals
who had key unpublished work. Each informant was asked
for literature they were aware of on the subject (published
and unpublished) and for the names of other individuals
who are knowledgeable in this area. Following several
iterations, the identiﬁed documents were reviewed. A draft
paper was prepared summarizing, for each domain, evi-
dence-based treatments, common problems with treatment
quality, and potential outcome indicators, instruments and
assessment modalities.
A national panel was assembled that included experts in
clinical treatment, quality improvement, and outcomes
assessment, as well as national and regional policy-makers.
In September 2005, this panel met via video conference.
Prior to the conference, panel members reviewed the results
oftheliterature review.During theconferencetherewas,for
each targeted domain, review of the evidence supporting
treatments in the domain and common problems with
treatment implementation. Within each domain, the panel
suggested constructsthat can identify (a) need for treatment,
and (b) change in status associated with treatment. For each
construct identiﬁed, alternative strategies and instruments
were discussed that make use of administrative or billing
data, medical records, patient self-assessment, clinician
assessment, or interviewer-based assessments. Recommen-
dations were made regarding alternative outcomes moni-
toring strategies. Panel members discussed and negotiated
areas of disagreement to increase consensus regarding the
recommendations. Following the conference, panel mem-
bers provided additional feedback by email and phone. A
document was prepared summarizing project consensus.
This was circulated to the Workgroup. An iterative process
of revisions led to the ﬁnal consensus reported in this
manuscript and endorsed by the Mental Health QUERI. The
authors of this manuscript have no known conﬂicts of
interest, and certify their responsibility for this article.
Results
Psychotic Symptoms
Symptom Severity
National guidelines concur that the treatment of psychosis
includes the prescription and use of appropriate medication
to control psychotic symptoms (American Psychiatric
Association 2004; Kreyenbuhl et al. 2010; Miller et al.
2004). By ‘‘appropriateness,’’ we mean the extent to which
clinicians are using effective strategies to address symp-
toms and side-effects (Young 1999). Almost all patients
who are in treatment for schizophrenia are prescribed an
antipsychotic medication (Lehman 1999). However, many
patients do not receive treatment that appropriately
addresses their symptoms or side-effects (Young et al.
1998). While choice of antipsychotic medication is con-
troversial, there is agreement that symptoms and side-
effects need to be managed, and there are strategies for
doing so. It is useful to identify which patients are not
receiving appropriate medication management for psy-
chosis, so that quality improvement efforts can focus on
their needs. The appropriateness of prescribing can be
evaluated using data on the severity of psychotic symptoms
in combination with data on medications prescribed
(Young et al. 1998). Unfortunately, administrative data and
chart review are not reliable or valid methods for assessing
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123psychosis (Young et al. 1998). One alternative data source
is patient self-assessment. Self-report measures of psy-
chosis severity can be found in Table 1.
Medication Adherence
Another common challenge is poor medication adherence
(Lacro et al. 2002). It is useful to identify which patients
are poorly adherent (see Table 1 for measures), so that
quality improvement efforts can implement interventions
that improve adherence. There are evidence-based strate-
gies that improve adherence, including cognitive-behav-
ioral approaches and long-acting injectable medications
(Zygmunt et al. 2002).
Treatment Resistance
Clozapine is the only antipsychotic that has superior efﬁ-
cacy in patients with treatment-refractory psychosis (Cha-
kos et al. 2001; McEvoy et al. 2006). According to national
guidelines, it should be used in patients who have had at
least two trials of other antipsychotic medications, but who
continue to have clinically signiﬁcant psychotic symptoms
(Kreyenbuhl et al. 2010). However, clozapine is more
complex to prescribe than other medications and is unde-
rused (Busch et al. 2004; Leslie and Rosenheck 2007). It is
likely that prescription data can be used to detect under-use
of clozapine. Treatment-refractory patients might be iden-
tiﬁed by detecting polypharmacy or high dosages of anti-
psychotic agents, but this approach has not yet been
validated. Another approach is to identify patients who
have persistent high levels of psychotic symptoms, ade-
quate adherence, and trials of at least two antipsychotic
medications. Alternatively, there is no reason to believe
that treatment resistance varies by clinic. Therefore, it
should be possible to establish a benchmark for clozapine
use that would reﬂect a reasonable prevalence of clozapine
use. It has been estimated that between 25 and 40% of
patients are refractory to treatment, and up to a half of these
individuals have substantial improvement with clozapine
(Kane and Marder 2005). High performing states have had
about 15% of patients on clozapine (Covell et al. 2002).
Recommendations
Further research is needed to determine the extent to which
assessment can inform efforts to improve treatment, reduce
psychosis, and improve psychosis-related outcomes, as
well as the optimal intervals for assessments. Adherence is
clearly important and can be monitored using pharmacy
data. To improve treatment of psychosis, it will be neces-
sary to systematically monitor the severity of psychosis in
patients. Self-report is a valid method for screening for
psychosis (Niv et al. 2007a), and the panel recommends the
BSI or BASIS-R. When psychosis assessment is combined
with data on medication prescribing, it is possible to iden-
tify patients who are not improving with their current reg-
imen. Under-use of clozapine can be detected with this
approach, or by comparing prescribing rates to benchmarks.
Medication Side-Effects
Most antipsychotic prescriptions are now for second gen-
eration agents. The most common side-effect with this
medication class is weight gain and related metabolic
complications, such as diabetes and hyperlipidemia. These
place patients at elevated risk for cardiovascular disease.
Less common side-effects include extrapyramidal side-
effects (especially tardive dyskinesia and akathisia), and
sexual dysfunction. National panels have developed rec-
ommendations for the screening and monitoring of anti-
psychotic medication side-effects (American Diabetes
Association 2004; American Psychiatric Association 2004;
Marder et al. 2004) (see Table 1 for measures).
Recommendations
The most important side-effects of second-generation
antipsychotic agents are weight gain and related medical
conditions. Patients can self-monitor their weight. Clini-
cians should routinely calculate BMI and perform labora-
tory monitoring for diabetes and hyperlipidemia according
to national guidelines. Weight and metabolic data can be
combined with data on prescribing and other treatments.
These data identify patients who are overweight or gaining
weight, and who are not receiving medication changes or
psychosocial interventions that improve weight (New-
comer 2007; Newcomer et al. 2008). Similarly, it is pos-
sible to identify patients with diabetes or hyperlipidemia
who are not receiving needed medical services.
Patients who are prescribed ﬁrst-generation agents
should be assessed for extrapyramidal side-effects. Patients
who are prescribed a ﬁrst-generation agent, risperidone, or
paliperidone should be monitored for sexual dysfunction.
Extrapyramidal and sexual side-effects can be reliably
evaluated by self-assessment.
Drug and Alcohol Use
Evidence-based care for schizophrenia and comorbid sub-
stance abuse consists of coordinated, simultaneous provi-
sion of mental health and substance abuse treatment
(McHugo et al. 2004). To ensure the provision of evidence-
based services for the dually diagnosed, it is necessary to
know when patients are abusing drugs or alcohol and, more
speciﬁcally, what substances are being used, the frequency
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Treatment target and outcome measures Description of outcome measures
Psychotic symptoms: symptom severity
Self-report
Revised Behavior And Symptom
Identiﬁcation Scale-Revised (BASIS-R)
The BASIS-R is a 24-item self-report instrument with six scales: psychosis, depression/
functioning, interpersonal problems, alcohol/drug use, self-harm, and emotional lability. The
BASIS-R has good reliability and validity (Eisen et al. 2004) and can accurately identify
moderate and severe psychosis (Niv et al. 2007a).
Symptom Checklist-90-Revised
(SCL-90-R)
The SCL-90-R is a 90-item self-assessment tool that measures psychoticism and paranoid
ideation in addition to seven other symptom scales. Although Derogatis reported acceptable
reliability and validity of the scale (Derogatis and Melisaratos 1983), subsequent studies
suggest that the instrument measures a single global distress factor instead of the nine
independent subscales reported (Clark and Friedman 1983; Rauter et al. 1996).
Brief Symptom Inventory (BSI) The BSI is a 53-item self-administered scale developed from the SCL-90-R. The BSI has good
psychometric properties and is an acceptable brief alternative to the SCL-90-R. However, its
validity for measuring psychosis is unclear. In a study of persons with schizophrenia, the
BSI had only one factor structure of general psychological distress (Hoe and Brekke 2009).
As with the SCL-90-R, the psychoticism and paranoid ideation scales did not emerge.
Another study compared the BSI to interviewer assessment and did not ﬁnd a relationship
between the psychoticism scale and the unusual thought content and hallucination items by
interview (Morlan and Tan 1998). They also did not ﬁnd a signiﬁcant relationship between
the BSI paranoid ideation scale and suspiciousness by interview. The BSI is, however,
capable of differentiating between those who were classiﬁed as high versus low on positive
symptoms by interview (Preston and Harrison 2003).
Psychotic symptoms: medication adherence
Administrative data
Medication possession ratio (MPR) MPR assesses the extent to which dispensed medications provide coverage for a given interval
(e.g., 6 months). MPR is inversely correlated with the probability of hospitalization (Gilmer
et al. 2004; Valenstein et al. 2002; Weiden et al. 2004). Although there does not seem to be a
distinct threshold at which partial antipsychotic adherence becomes problematic, taking
80% or more of prescribed medications (MPRs C 0.8) has been used as a cut-point
(Osterberg and Blaschke 2005). A limitation of this approach is that calculations require
6 months or more of data, so results may be obtained too late to be clinically useful.
Gap measure Gap measure is based on gaps in medication prescribing or failure to reﬁll prescriptions
(Bryson et al. 2007). A gap measure assessed 10 days after a reﬁll is due can provide
information that is timely enough to allow clinicians to intervene, though with a greater
number of false positives (Law et al. 2008).
Microelectronic monitoring systems These pill bottles have a bottle cap that records the date and time of every bottle opening.
Monitoring bottles are costly to use widely.
Blood and urine tests Blood and urine tests can identify patients who have no recent medication ingestion (Cramer
1991). However, this is a relatively expensive option that is not well accepted by clinicians
and patients.
Self-report
Count missed doses This approach appears to be inaccurate (Byerly et al. 2007; Cramer 1991).
Drug Attitude Inventory Assesses attitudes toward medications rather than adherence behavior (Hogan et al. 1983).
Psychotic symptoms: treatment resistance
Administrative data Set a benchmark to detect under-use of clozapine.
Self-report Use instruments described above to identify patients who may beneﬁt from clozapine (i.e., are
medication adherent and have persistent high levels of psychosis).
Medication side-effects
Administrative data
Body Mass Index (BMI) BMI is calculated from height and weight, and is the most commonly recommended metric for
monitoring weight gain. A BMI of 18.5–24.9 is normal, 25.0–29.9 is overweight, and 30 or
higher is obese. Guidelines indicate that BMI should be recorded before medication
initiations or changes, at every follow-up visit for 6 months following medication initiation
or change, and at least every 3 months thereafter (Marder et al. 2004).
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Treatment target and outcome measures Description of outcome measures
Fasting glucose or HgA1c Hyperglycemia and diabetes can be tracked through monitoring of fasting plasma glucose values.
However, it may be difﬁcult for patients with schizophrenia to fast reliably. Use of random blood
glucose values, or HgA1c, is likely more practical. The possibility of diabetes should be considered
in the event of fasting plasma glucose[126 mg/dl, random plasma glucose value[200 mg/dl, or
HgA1c[6.1% (Marder et al. 2004). Testing should be done before beginning a new medication.
Patients with diabetes risk factors or weight gain should have monitoring 4 months after starting a
new medication and annually thereafter.
Lipids A fasting lipid panel should be completed at least every 5 years.
Self-report
Height and weight Patients can also report their weight to the clinician, though this may be inaccurate because patients
may not weigh themselves regularly, have unreliable scales, or inaccurate memory.
LUNSERS The Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS)(Day et al. 2005) covers
extrapyramidal and other side-effects but is limited in its assessment of sexual side-effects.
Arizona Sexual Experience Scale
(ASEX)
TheASEXisa5-itemscalecommonlyusedtoassesssexualdysfunctionandhasbeenvalidatedamong
patientswithschizophrenia(Byerlyetal.2006;McGahueyetal.2000).Sexualfunctioningshouldbe
assessed prior to antipsychotic medication initiation and yearly thereafter (Marder et al. 2004). If the
patient is prescribed a ﬁrst-generation antipsychotic, risperidone or paliperidone, sexual functioning
should be assessed at every visit until dose is stabilized.
Comorbid drug and alcohol use
Self-report
Michigan Alcoholism Screening Test
(MAST)
The MAST is a 25-item yes/no questionnaire used to identify alcohol abuse disorders (Selzer 1971).
Although the MAST has been shown to be reliable and valid in non-psychiatric populations, it has
generated mixed results in patients with schizophrenia (McHugo et al. 1993; Toland and Moss
1989).
CAGE The CAGE, a 4-item screen for subjective negative consequences of alcohol abuse, has acceptable
sensitivity and speciﬁcity in psychiatric populations (Mayﬁeld et al. 1974).
Alcohol Use Disorders Identiﬁcation
Test (AUDIT)
The AUDIT screens for alcohol abuse by identifying harmful personal and social consequences of
alcohol use (Bohn et al. 1995). This 10-item questionnaire is brief, easily administered, and is
highly reliable and valid in schizophrenia (Dawe et al. 2000; Saunders et al. 1993). The AUDIT
requires only a seventh grade reading level and is a better measure of recent alcohol consumption
than the MAST or the CAGE, which focus on lifetime use (Hays et al. 1995).
AUDIT-C The AUDIT-C is a brief version of the AUDIT consisting of the three consumption-related items of
the AUDIT (Bush et al. 1998; Dawson et al. 2005).
T-ACE The T-ACE (Russell 1994) is a 4-item, self-report alcohol screen.
TWEAK The TWEAK (Russell and Bigler 1979) is a 4-item, self-report alcohol screen.that consists of items
from the MAST, the CAGE, and the T-ACE (Russell 1994). The TWEAK was slightly more
accurate than the T-ACE in detecting alcohol abuse in patients with schizophrenia, and both of
these questionnaires have been shown to be more accurate than the MAST or the CAGE (Russell
1994; Wolford et al. 1999).
Drug Abuse Screening Test (DAST) The DAST (Skinner 1982) is a leading self-administered drug abuse screen and has been validated in
psychiatric populations (Staley and el-Guebaly 1990).
ASSIST The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) is a 8-item scale used to
detect substance abuse in a primary care setting (WHO ASSIST Working Group 2002).
Two-item conjoint screen (TICS) The Two-Item Conjoint Screen (TICS) has been used in primary care to identify patients with current
alcohol or drug problems (Brown et al. 1997).
Comorbid depression and suicidality
Self-report
Beck Depression Inventory—II (BDI-II) The BDI—II is a 21-item scale with good reliability and validity (Beck et al. 1996).
BDI—primary care version (BDI—PC) The BDI—PC is a 7-item screening device designed for use in primary care settings (Beck 1993).
Patient Health Questionnaire-9 (PHQ-9) The PHQ-9 is a 9-item, self-report scale that assesses frequency of depressive symptoms over the
past 2 weeks (Kroenke et al. 2001) and has been shown to be responsive to improvements with
treatment (Lowe et al. 2004).
Beck Scale for Suicidal Ideation (BSI) The BSI (Beck and Steer 1991) is a 21-item, self-report measure that screens for suicidality and has
good psychometric properties in schizophrenia (Pinninti et al. 2002). Alternatives include the two-
item Clinical Suicidality Assessment scale (CSA)(Pfeffer et al. 1988), and the two-item self-harm
subscale from the BASIS-R.
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123and amount of use, and impairments in functioning
resulting from substance use. Objective assessment of
substance use, e.g., urine toxicology screens and breatha-
lyzer data, is the gold standard for guiding treatment. Since
objective data are often not available, monitoring may also
be based on administrative data, clinician assessment, or
self-assessment. Administrative data tend to be of limited
use because rates of detection and documentation of sub-
stance abuse in routine care are low and of questionable
accuracy. Also, when diagnoses are made, there is often
limited documentation regarding the severity and recency
of the use. Self-administered assessments may be useful in
a clinical setting as they are easier to obtain than clinician-
administered assessments and have better predictive utility
(Wolford et al. 1999). Patients appear to be more forth-
coming with self-administered assessments than during
interviews. Self-report measures of alcohol and drug use
can be found in Table 1.
Recommendations
Regular screening should be used to identify substance
abuse and associated problems and to guide treatment.
Self-administered patient reports can provide data of sim-
ilar or better quality than clinician assessment while
reducing clinician burden. The AUDIT or AUDIT-C can be
Table 1 continued
Treatment target and outcome measures Description of outcome measures
Clinical Suicidality Assessment Scale
(CSA)
The CSA is a 2-item suicidiality screen (Pfeffer et al. 1988).
BASIS-R The BASIS-R includes in 2-item self-harm subscale (Eisen et al. 2004).
Family and caregivers
Administrative data Hospitalization data.
Self-report
Family Environment Scale (FES) The FES is a 90-item, true/false questionnaire measuring family cohesion, conﬂict, and
expressiveness (Morisky et al. 1986).
Family Attitude Scale (FAS) The FAS is a 30-item measure of family stress and expressed anger (Kavanagh et al. 1997).
Level of Expressed Emotion Scale
(LEE)
The LEE is a 60-item measure of expressed emotion (Cole and Kazarian 1988).
Patient Rejection Scale (PRS) The PRS an 11-item measure of relatives’ hostile and critical attitudes toward their ill family member
(Kreisman et al. 1979).
FACES IV FACES IV is a 42-item measure that yields scores in a number of domains, including family
cohesion, adaptability, communication, and satisfaction (Gorall et al. 2004).
McMaster Family Assessment Device The McMaster Family Assessment Device is a 53-item measure that assesses the health of family
functioning (Miller et al. 1985).
Quality of Life Interview (QOLI) Items from the QOLI can be used to assess frequency of family contact and satisfaction with family
relationships (Lehman 1988).
Vocational functioning
Self-report
Employment status Employment status (i.e., competitive employment, sheltered employment, unemployed); number of
hours worked per week; number of paid work days in the past 30 days; job tenure; salary per hour.
While dollars earned is a critical outcome, there has been limited research on the validity of
obtaining this information from patients.
Indiana Job Satisfaction Scale (IJSS) The IJSS is a brief job satisfaction questionnaire developed for individuals with severe mental illness
(Resnick and Bond 2001).
Social Attainment Scale—II (SAS-II) SAS-II has a patient self-report version that measures missed days of work, objective and subjective
performance adequacy, interpersonal friction, distress, and satisfaction (Schooler et al. 1979). For
patients who are unemployed, an item from the SAS-II can be used to measure desire to work.
Quality of Life Interview (QOLI) The QOLI includes a number of items assessing employment status and satisfaction.
Community tenure and housing
Administrative data Hospitalization data.
Self-report
Residential Follow-Back Calendar The Residential Follow-Back calendar records days of stable community housing, institutional days,
homeless days, and marginal homelessness (Bebout et al. 1997).
Schizophrenia Outcomes Module The Schizophrenia Outcomes Module includes valid measures of housing status (Cuffel et al. 1997).
Quality of Life Interview (QOLI) The QOLI includes items assessing satisfaction with housing.
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123used to screen for alcohol use disorders and the DAST can
be used to screen for drug use disorders.
Depression and Suicidality
Depressive symptoms have been shown to be important
determinants of quality of life among patients with
schizophrenia. Some treatment guidelines support the use
of antidepressant medication in this population for those
who continue to experience depression after a reduction in
positive psychotic symptoms (American Psychiatric
Association 2004). These guideline recommendations have
been made even though no pharmacological or psychoso-
cial treatments for comorbid depression and schizophrenia
have consistently proven to improve outcomes. Suicide is a
common cause of premature death in schizophrenia, and
individuals with schizophrenia are nine times as likely to
die by suicide as the general population. Self-report mea-
sures of depression and suicidality are valid, and can be
found in Table 1.
Recommendations
Routine assessment of depression and suicidality is
important, though there is limited evidence to guide the
frequency of these assessments. Screening and assessment
for depression can be done by self-assessment using the
BDI or PHQ-9. The PHQ-9 is quicker to administer. The
BASIS-R suicidality items are a reasonable choice to
screen for suicidality. However, further research is needed
to develop and evaluate psychosocial and medication
interventions that improve depression and suicidality in
schizophrenia.
Family and Caregivers
Family psychoeducation is included in national treatment
guidelines based on its positive effect on outcomes for
patients and their family members (Kreyenbuhl et al.
2010). Family interventions have been shown to reduce
relapse and hospitalizations, and have broader beneﬁts on
psychosocial adjustment, such as vocational functioning
(McFarlane et al. 2000; Pilling et al. 2002; Pitschel-Walz
et al. 2001). Despite mandates to implement family ser-
vices and family-driven care (President’s New Freedom
Commission on Mental Health 2003), research indicates
that most families do not have even minimal contact with
mental health clinicians (Resnick et al. 2005). To ensure
that families and other caregivers have access to services
and clinicians, it is necessary to know which patients are in
close contact with family or caregivers. This information is
not reliably found in administrative data or medical
records. However, it can be reliably obtained through
patient self-report. Although there is no cut-off for intensity
of contact that deﬁnes an ‘‘involved caregiver,’’ this is
sometimes deﬁned as contact of at least several times a
month. Research on the potential beneﬁts of family
involvement suggests that high priority should be given to
engaging the families of patients who have severe psy-
chotic symptoms, low medication adherence, or who report
a negative family environment. Strategies for identifying
the ﬁrst two groups are found in the section on psychotic
symptoms. There are several scales that assess family
environment and relationships (see Table 1). However,
research does not support limiting interventions to families
with particular scores on these instruments. Clinicians may
ﬁnd them helpful, but none is recommended for routine
assessment. Structured, long-term family services have
been associated with reduced psychosis and less hospital-
ization. Evaluation of psychosis is described above. Hos-
pitalizations and related crisis services can be identiﬁed
using a combination of administrative data and self-report.
There are also established scales to measure family out-
comes, including knowledge of illness and family burden,
though the validity and reliability of these instruments is
uncertain.
Recommendations
Family members and other caregivers who might beneﬁt
from increased involvement in care should be identiﬁed
and engaged through outreach. The presence of an involved
family or caregiver can be ascertained by patient self-
report. At a minimum, caregivers should be provided with
information, given access to the treatment team, and given
referrals to family support organizations. Evidence-based
family interventions should be offered. In regard to the
outcomes of family services, relevant domains for assess-
ment include psychotic symptoms, medication compliance,
and hospitalization.
Vocational Functioning
Supported employment (SE) is an evidence-based practice
that substantially increases rates of competitive employ-
ment in populations with schizophrenia (Crowther et al.
2001). According to guidelines, SE should be offered to
individuals who are not employed and wish to ﬁnd work,
and to individuals who are currently working but ﬁnd their
work unsatisfying or too stressful (Kreyenbuhl et al. 2010).
It is often impossible to determine from administrative data
or medical records which patients should be offered SE,
since work status and goals are not consistently docu-
mented. While research on assessment is limited, it is likely
that these domains can be assessed by self-report (see
Table 1).
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Self-report measures should be used to identify eligible
patients and to assess the outcomes of SE. Employment
status can be assessed by self-report, including dollars
earned and hours worked. Job satisfaction can be assessed
using the Indiana Job Satisfaction Scale.
Community Tenure and Housing
A key component of recovery for people with schizo-
phrenia is successfully living in their communities; for
example, not being hospitalized, incarcerated, or homeless.
About 10% of people with schizophrenia are homeless
(American Psychiatric Association 2004), and there is a
spectrum of autonomy in housing arrangements. The
Workgroup saw value in measuring the strength of an
individual’s integration into their community, but there was
little research or consensus regarding how to measure this
construct. Therefore, the focus was restricted to housing
and duration of community tenure.
Some individuals with schizophrenia require speciﬁc
psychosocial services to live in the community or require
long-term, structured living environments. Assertive com-
munity treatment (ACT) is effective in improving com-
munity tenure and is included in national treatment
guidelines. Patients may be eligible for ACT if they are
homeless, hospitalized, incarcerated, or at high risk for
these outcomes. Repeated hospitalizations can be identiﬁed
using billing or administrative data. Since these datasets
typically do not include all hospitalizations, they can be
augmented by self-report. In addition to ACT, there are
other care models that improve access to housing (Young
and Magnabosco 2004).
Important outcomes of ACT and housing services
include housing status and satisfaction with one’s living
situation. Administrative and billing data typically lack
accurate and current information regarding community
tenure and housing. There has been limited research on the
validity of self-administered measures of housing, although
one study found patient reports of housing status to be
highly correlated with family and clinician reports (Cuffel
et al. 1997). There are widely used interviewer-adminis-
tered instruments that are likely to provide an accurate
assessment of housing status, including homelessness, and
stable or unstable community housing (Table 1).
Consumer-driven interventions, such as peer support or
consumer outreach workers, also show promise for
improving community tenure (Chinman et al. 2006).
However, there is insufﬁcient evidence to know which
individuals should receive consumer-driven interventions,
how to provide them, or how to characterize their effec-
tiveness. They are not yet covered in national treatment
guidelines, and the Workgroup was not able to characterize
relevant needs for outcome assessment.
Recommendations
Eligibility for ACT should be determined using a combi-
nation of administrative and patient self-administered data
assessing housing, hospitalizations and incarceration. The
major challenge to using these data to evaluate access to
ACT is the nature of the patient population being served,
which may be homeless and minimally engaged in treat-
ment. Novel approaches for identifying eligible individuals
for ACT should be developed and studied. In regard to
housing services, homelessness and unstable housing
should be assessed by self-assessment. Risk for home-
lessness, while important, has not been well characterized.
Satisfaction with housing should be assessed using items
from the Quality of Life Interview (Lehman 1988).
Discussion
The Schizophrenia Outcomes Workgroup used literature
review, expert interviews, and a national expert panel
process to increase consensus regarding outcomes moni-
toring strategies that can be used to support quality
improvement and the delivery of evidence-based treat-
ments for schizophrenia. It is clear that outcome mea-
surement is better developed in some domains than others.
Good consensus was reached for the domains of psychotic
symptoms, medication side-effects, drug and alcohol use,
depression, family and caregivers, vocational functioning,
community tenure, and housing. In these domains, there are
well developed, validated, self-report outcomes assessment
instruments, and often multiple excellent choices for rou-
tine outcomes monitoring. However, there are areas that
would beneﬁt from further research on measurement,
including, for example, identifying eligible patients for
clozapine or supported employment. It was not possible to
develop consensus in other domains, such as negative
symptoms, cognitive symptoms, and use of peer support
interventions, because efﬁcacy research is not sufﬁciently
developed. National treatment guidelines offer limited
guidance regarding treatments that should be provided to
patients and, therefore, outcomes to be monitored.
Although there are high quality outcomes assessment
instruments, some assessment strategies are much easier
than others to implement in routine treatment settings. The
most feasible strategies for obtaining outcomes data are the
use of administrative or billing data, and self-administered
assessments. Administrative data are typically not designed
for this purpose, and often contain inaccurate or incomplete
information on outcomes and limited clinical content. This
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Electronic Medical Records (EMRs). However, even with
EMRs, outcomes data are inconsistently documented or
encoded in ﬁelds that are readily usable for quality
improvement (Young 2007). To standardize medical
records data, healthcare organizations sometimes rely on
clinicians to document outcomes, an approach that has not
worked well. Although many clinicians could be trained to
high levels of reliability in standardized instruments, they
typically do not have the time or interest necessary for
training, routine performance, and entry of outcomes data
into medical records.
Self-administered patient assessments are another strat-
egy for outcome monitoring. They requires less time from
busy clinicians, do not require repeated trainings, and
alleviate concerns about clinician gaming of assessments.
Methods of self-assessment vary and can be determined by
the needs of speciﬁc projects and healthcare organizations.
Methods of self-assessment have included traditional paper
and pencil forms, scannable forms, electronic self-entry
devices, and internet access by patients. Electronic devices
at clinics can include dedicated kiosks or tablet computers
with touch-screen and audio interfaces. Self-entry systems
can generate reliable and valid data, are well accepted by
clinic populations with schizophrenia, and can be feasible
to implement in clinic settings (Chinman et al. 2004, 2007).
For quality improvement, it is necessary to know which
patients would beneﬁt from speciﬁc treatments, and which
of these patients have not been receiving those treatments.
The Workgroup did not review methods for monitoring the
utilization or appropriateness of services that patients
receive. However, there was agreement that, in addition to
monitoring outcomes, it will also be important to monitor
the provision of effective care. For psychosocial treatments
in particular, it is important to monitor the extent to which
treatments demonstrate ﬁdelity to practices that are known
to improve outcomes.
This project had a number of limitations. First, the
outcome strategies and instruments recommended are not
intended to replace clinical decision-making in individual
patients. Rather, they were developed to support organi-
zational efforts to improve care in populations of patients.
Also, the instruments reviewed are not an exhaustive list.
There are likely to be other instruments with good psy-
chometric properties that are suitable for monitoring out-
comes in these domains. In any speciﬁc instance of quality-
oriented outcomes monitoring, selection of speciﬁc strate-
gies and instruments must be a function of the goals of the
project and the characteristics of the healthcare system.
Healthcare organizations have succeeded in improving
care by making use of quality improvement that includes
routine collection of outcome data. The routine and sys-
tematic collection of data allows for identiﬁcation of unmet
needs, and redesign of services to improve access to
effective practices and improve outcomes. There have been
fewer successes with this approach in schizophrenia than in
other chronic medical disorders, and there are speciﬁc
challenges to collection and encoding of outcomes data in
this population. However, the Workgroup believes that
there is substantial potential to improve access to effective
treatments in populations with schizophrenia. This begins
with systematic monitoring of outcomes. Providing out-
comes data to clinicians would not by itself be expected to
improve the quality of care (Fihn et al. 2004; Stone et al.
2002). Rather, this data needs to be used as part of sys-
tematic projects to reorganize service delivery. Systematic
research will bee needed to evaluate these efforts to
improve care.
There was strong consensus regarding viable strategies
for routine outcomes monitoring. There are some domains,
such as psychotic symptoms, medication side-effects, and
medication adherence, where there are existing instruments
and data sources that are ready now for widespread
implementation and use. There are other domains, such as
clozapine, employment, and community reintegration
where useful instruments are available, but measurement
could be substantially strengthened with additional
research. It was not possible, or desirable, to deﬁnitively
recommend one speciﬁc instrument and measurement
strategy for all quality improvement efforts. Each mea-
surement strategy and instrument has pros and cons that
must be weighed. And, to be successful, quality improve-
ment needs to attend both to evidence and also local con-
text when selecting measurement strategies. Therefore,
when there were multiple acceptable instruments, the
Workgroup did not select one choice, but left this choice to
the quality improvement project that will use the data. With
regard to alternative measurement strategies, patient self-
report appears to be the most broadly feasible method in
many domains. Self-report should be supplemented, where
helpful, by clinician documentation and administrative
data. Whatever path an organization selects with regard to
domains, instruments, and data collection strategies, there
are important opportunities to use outcomes data as part of
projects to improve care for schizophrenia.
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